{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T12:45:15Z","timestamp":1648903515742},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Severe acute exacerbation in chronic hepatitis B could lead to mortality in some patients unless timely liver transplantation is performed. The baseline bilirubin level has been reported to be an important prognostic factor for mortality. Here we conducted a prospective observational study to examine the clinical performance of this predictor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>Twenty-one consecutive chronic hepatitis B patients experiencing severe acute exacerbation were treated with either telbivudine or entecavir. The clinical characteristics at baseline and week-2 were documented and correlated with mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 21 patients included, 9 had baseline bilirubin &gt;10 mg\/dL. Four of these 9 patients (44.4%) eventually died, whereas all other patients survived. During the initial 2-week period, the change of bilirubin was \u22121.2 mg\/dl in the survivors, but was +8.05 mg\/dl in the mortalities (P = 0.009). When this on-treatment factor was combined, 5 of the 21 patients had baseline bilirubin &gt; 10 mg\/dL plus an increase of bilirubin level at week-2. Of these 5 patients, 4 (80%) died. Thus, by combining the baseline and on-treatment bilirubin levels, a positive predictive value of 80% and a negative predictive value of 100% could be achieved. Other significant on-treatment mortality predictors (at week-2) included higher international normalized ratio of prothrombin time (2.75 vs. 1.3, P = 0.004), higher model for end-stage liver disease score (30 vs. 17, P = 0.006), lower alpha-fetoprotein level (36.3 vs. 459.6 ng\/mL, P = 0.039), and more rapid deterioration of the estimated glomerular filtration rate (eGFR) (P = 0.008). Interestingly, during the course, deterioration of eGFR was statistically significant in entecavir-treated (P = 0.028), but not in telbivudine-treated patients. Additionally, the patients treated with telbivudine had significant increase in serum alpha-fetoprotein (27.9 to 191.9 ng\/ml, P = 0.046) in the first 2 weeks, whereas the corresponding feature was not found in those treated with entecavir (P = 0.139).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this prospective observational study, we discovered that the baseline and on-treatment bilirubin levels should be combined to achieve a better predictive value. Telbivudine might have a renoprotective effect in addition to its efficacy in viral suppression in patients with severe acute exacerbation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-6-349","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T12:14:02Z","timestamp":1378124042000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study"],"prefix":"10.1186","volume":"6","author":[{"given":"Yi-Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"key":"2394_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.1840070106","volume":"7","author":"YF Liaw","year":"1987","unstructured":"Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ: Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology. 1987, 7: 20-23. 10.1002\/hep.1840070106.","journal-title":"Hepatology"},{"key":"2394_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0168-8278(90)90069-4","volume":"10","author":"AS Lok","year":"1990","unstructured":"Lok AS, Lai CL: Acute exacerbations in Chinese patients with chronic hepatitis B (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol. 1990, 10: 29-34. 10.1016\/0168-8278(90)90069-4.","journal-title":"J Hepatol"},{"key":"2394_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","volume":"38","author":"RN Chien","year":"2003","unstructured":"Chien RN, Lin CH, Liaw YF: The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003, 38: 322-327.","journal-title":"J Hepatol"},{"key":"2394_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1440-1746.2009.05924.x","volume":"24","author":"VW Wong","year":"2009","unstructured":"Wong VW, Chan HL: Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol. 2009, 24: 1179-1186. 10.1111\/j.1440-1746.2009.05924.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2394_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12072-008-9106-x","volume":"3","author":"SK Sarin","year":"2009","unstructured":"Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009, 3: 269-282. 10.1007\/s12072-008-9106-x.","journal-title":"Hepatol Int"},{"key":"2394_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0168-8278(88)80475-6","volume":"7","author":"C Vickers","year":"1988","unstructured":"Vickers C, Neuberger J, Buckels J, McMaster P, Elias E: Transplantation of the liver in adults and children with fulminant hepatic failure. J Hepatol. 1988, 7: 143-150. 10.1016\/S0168-8278(88)80475-6.","journal-title":"J Hepatol"},{"key":"2394_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1046\/j.1365-2893.2002.00385.x","volume":"9","author":"HL Chan","year":"2002","unstructured":"Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ: The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat. 2002, 9: 424-428. 10.1046\/j.1365-2893.2002.00385.x.","journal-title":"J Viral Hepat"},{"key":"2394_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1086\/374226","volume":"36","author":"MF Yuen","year":"2003","unstructured":"Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, Doutreloigne J, Bogaerts V, Wong BC, Fan ST, Lai CL: Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis. 2003, 36: 979-984. 10.1086\/374226.","journal-title":"Clin Infect Dis"},{"key":"2394_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000080877","volume":"47","author":"A Tsubota","year":"2004","unstructured":"Tsubota A, Arase Y, Suzuki Y, Suzuki F, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H: Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology. 2004, 47: 335-341. 10.1159\/000080877.","journal-title":"Intervirology"},{"key":"2394_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1440-1746.2004.03534.x","volume":"20","author":"A Tsubota","year":"2005","unstructured":"Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Dumada H: Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005, 20: 426-432. 10.1111\/j.1440-1746.2004.03534.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2394_CR11","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.clinthera.2006.12.016","volume":"28","author":"CY Dai","year":"2006","unstructured":"Dai CY, Chuang WL, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Huang JF, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML: Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. Clin Ther. 2006, 28: 2081-2092. 10.1016\/j.clinthera.2006.12.016.","journal-title":"Clin Ther"},{"key":"2394_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006, 354: 1001-1010. 10.1056\/NEJMoa051285.","journal-title":"N Engl J Med"},{"key":"2394_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, BEHoLD AI463027 Study Group: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006, 354: 1011-1020. 10.1056\/NEJMoa051287.","journal-title":"N Engl J Med"},{"key":"2394_CR14","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe Study Group: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007, 357: 2576-2588. 10.1056\/NEJMoa066422.","journal-title":"N Engl J Med"},{"key":"2394_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group: 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009, 136: 486-495. 10.1053\/j.gastro.2008.10.026.","journal-title":"Gastroenterology"},{"key":"2394_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hep.24361","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E: Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011, 54: 91-100. 10.1002\/hep.24361.","journal-title":"Hepatology"},{"key":"2394_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.23952","volume":"53","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER: Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011, 53: 62-72. 10.1002\/hep.23952.","journal-title":"Hepatology"},{"key":"2394_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","volume":"52","author":"JH Shim","year":"2010","unstructured":"Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ: Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010, 52: 176-182. 10.1016\/j.jhep.2009.11.007.","journal-title":"J Hepatol"},{"key":"2394_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jhep.2010.06.043","volume":"54","author":"VW Wong","year":"2011","unstructured":"Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, Sung JJ, Chan HL: Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 2011, 54: 236-242. 10.1016\/j.jhep.2010.06.043.","journal-title":"J Hepatol"},{"key":"2394_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","volume":"19","author":"HL Chan","year":"2012","unstructured":"Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A: Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-na\u00efve patients with HBV-related decompensated cirrhosis. J Viral hepat. 2012, 19: 732-743. 10.1111\/j.1365-2893.2012.01600.x.","journal-title":"J Viral hepat"},{"key":"2394_CR21","unstructured":"United network for organ sharing. MELD\/PELD calculator documentation. http:\/\/www.unos.org\/docs\/MELD_PELD_Calculator_Documentation.pdf. Accessed April 2011"},{"key":"2394_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999, 130: 461-470. 10.7326\/0003-4819-130-6-199903160-00002.","journal-title":"Ann Intern Med"},{"key":"2394_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Lente FV, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009, 150: 604-612. 10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"key":"2394_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.24109","volume":"53","author":"H Garg","year":"2011","unstructured":"Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A: Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011, 53: 774-780. 10.1002\/hep.24109.","journal-title":"Hepatology"},{"key":"2394_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1600-0676.1984.tb00942.x","volume":"4","author":"YF Liaw","year":"1984","unstructured":"Liaw YF, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY: Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver. 1984, 4: 301-306.","journal-title":"Liver"},{"key":"2394_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.7326\/0003-4819-80-2-156","volume":"80","author":"GG Karvountzis","year":"1974","unstructured":"Karvountzis GG, Redeker AG: Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Ann Intern Med. 1974, 80: 156-60. 10.7326\/0003-4819-80-2-156.","journal-title":"Ann Intern Med"},{"key":"2394_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/hep.1840080504","volume":"8","author":"D Bernuau","year":"1988","unstructured":"Bernuau D, Poliard A, Feldmann G: In situ cellular analysis of a-fetoprotein gene expression in regenerating rat liver after partial hepatectomy. Hepatology. 1988, 8: 997-1005. 10.1002\/hep.1840080504.","journal-title":"Hepatology"},{"key":"2394_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s005350200099","volume":"37","author":"SS Yang","year":"2002","unstructured":"Yang SS, Chen KS, Lai YC, Wu CH, Chen TK, Lee CL, Chen DS: Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. J Gastroenterol. 2002, 37: 626-632. 10.1007\/s005350200099.","journal-title":"J Gastroenterol"},{"key":"2394_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/hep.20511","volume":"41","author":"L Schmidt","year":"2005","unstructured":"Schmidt L, Dalhoff K: Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology. 2005, 41: 26-31. 10.1002\/hep.20511.","journal-title":"Hepatology"},{"key":"2394_CR30","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.3748\/wjg.v13.i42.5552","volume":"13","author":"AP Betrosian","year":"2007","unstructured":"Betrosian AP, Agarwal B, Douzinas EE: Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007, 13: 5552-5559.","journal-title":"World J Gastroenterol"},{"key":"2394_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1053\/ajkd.2003.50035","volume":"41","author":"DS Sherman","year":"2003","unstructured":"Sherman DS, Fish DN, Teitelbaum I: Assessing renal function in cirrhotic patients: Problems and pitfalls. Am J Kidney Dis. 2003, 41: 269-278. 10.1053\/ajkd.2003.50035.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-6-349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:28:54Z","timestamp":1630546134000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-6-349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2394"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-6-349","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,2]]},"assertion":[{"value":"25 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"349"}}